Pharmacology

Action Mechanism of Action Reference
INHIBITOR Lymphocyte activation gene 3 protein inhibitor
Primary Target
LAG3 (CD223)

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Colorectal Neoplasms 3 D015179 ClinicalTrials
Colorectal Neoplasms 3 D015179 ClinicalTrials
Melanoma 3 D008545 ClinicalTrials
Melanoma 3 D008545 ClinicalTrials
Melanoma 3 D008545 ClinicalTrials
Colorectal Neoplasms 3 D015179 ClinicalTrials
Carcinoma, Renal Cell 2 D002292 ClinicalTrials
Nasopharyngeal Carcinoma 2 D000077274 ClinicalTrials
Multiple Myeloma 2 D009101 ClinicalTrials
Carcinoma, Squamous Cell 2 D002294 ClinicalTrials
Carcinoma, Hepatocellular 2 D006528 ClinicalTrials
Leukemia, Myeloid, Acute 2 D015470 ClinicalTrials
Neoplasms 2 D009369 ClinicalTrials
Chordoma 2 D002817 ClinicalTrials
Carcinoma, Squamous Cell 2 D002294 ClinicalTrials
Colonic Neoplasms 2 D003110 ClinicalTrials
Neoplasms 2 D009369 ClinicalTrials
Uveal Melanoma 2 D000098943 ClinicalTrials
Carcinoma, Merkel Cell 2 D015266 ClinicalTrials
Liver Neoplasms 2 D008113 ClinicalTrials
Carcinoma, Non-Small-Cell Lung 2 D002289 ClinicalTrials
Carcinoma, Basal Cell 2 D002280 ClinicalTrials
Sarcoma 2 D012509 ClinicalTrials
Stomach Neoplasms 2 D013274 ClinicalTrials
Lymphoma 1 D008223 ClinicalTrials
Lymphoma, Large B-Cell, Diffuse 1 D016403 ClinicalTrials
Esophageal Neoplasms 1 D004938 ClinicalTrials
Hematologic Neoplasms 1 D019337 ClinicalTrials
Glioblastoma 1 D005909 ClinicalTrials
Lymphoma, Follicular 1 D008224 ClinicalTrials
Gliosarcoma 1 D018316 ClinicalTrials

Cross References

Resources Reference
CAS NUMBER 1673516-98-7
ChEMBL CHEMBL3990044
FDA SRS AF75XOF6W3
Guide to Pharmacology 9536